Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
More people are addicted to marijuana, but fewer of them are seeking help, experts say - 2UK can legally stop shadow fleet tankers, ministers believe
- 3The Best Computer games Ever
- 4Two IDF officers, civilian face indictment in alleged Gaza aid-truck smuggling scheme
- 56 Solid Vehicle Fix Administrations to Keep Your Vehicle in Prime Condition
- Feeling wonder every day improves our health. Here’s how to do it.
- The biggest black hole breakthroughs of 2025
- Vote In favor of Your Favored Kind Of Bites
- Kate Middleton and Prince William unveil annual family Christmas card photo with George, Charlotte and Louis
- International issues on the agenda as Frances's Macron visits China
- How effective is the flu shot this year? New report shows promising results
- Virtual Domains d: A Survey of \Inundation and Ongoing interaction Mechanics\ Computer game
- Norovirus is spreading earlier again this year, wastewater data shows
- Rubble, mud and hair: How to rebuild a home in Gaza
